Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team

Apr 09, 2020•over 5 years ago

Amount Raised

$60 Million

Round Type

series b

Cambridge

Description

Tango Therapeutics, a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of an oversubscribed Series B financing of $60 million led by Boxer Capital of the Tavistock Group. Cormorant Asset Management and Casdin Capital are additional new investors in the round.

Company Information

Company

Tango Therapeutics

Location

Cambridge, Maryland, United States

About

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. The company is focused on three core areas: counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations that will be more effective than single agent therapy. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures and announced a strategic collaboration with Gilead Sciences in November 2018 with a $50 million upfront payment. For more information, please visit www.tangotx.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information